Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial
Amy K. Mottl, Jennifer B. Green, Sung Gyun Kim, Hiddo J.L. Heerspink et al.
Journal
Nephrology Dialysis Transplantation
Topics
Diabetes Treatment and Management
article
Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial
Amy K. Mottl, Jennifer B. Green, Sung Gyun Kim, Hiddo J.L. Heerspink, Masaomi Nangaku, Katja Rohwedder, Johannes F.E. Mann, Julio Rosenstock, Janet B. McGill, Rajiv Agarwal, Charlie Scott, Muthiah Vaduganathan, Peter R Rossing, Li Li, Na Li
article en
Abstract
No abstract available for this paper.
Publication Tag
Nephrology Dialysis TransplantationVol. 41(1)
Institutions
University of Copenhagen (DK), Brigham and Women's Hospital (US), University of North Carolina Health Care (US), University Medical Center Groningen (NL), Steno Diabetes Centers (DK), Harvard University (US), Bayer (United States) (US), Duke University (US), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Washington University in St. Louis (US), Clinical Research Institute (US), Richard L. Roudebush VA Medical Center (US), KfH Kuratorium für Dialyse und Nierentransplantation (DE), Velocity Clinical Research (United States) (US), Bayer (China) (CN), Hallym University Sacred Heart Hospital (KR), Indiana University – Purdue University Indianapolis (US), Bayer (Germany) (DE), The University of Tokyo (JP)
Funders
Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Bayer, Sanofi, Gilead Sciences, Alnylam Pharmaceuticals, Regeneron Pharmaceuticals, Bayer HealthCare, Novo Nordisk, Astellas Pharma, Akebia Therapeutics, National Institutes of Health, Chugai Pharmaceutical, Daiichi Sankyo Europe